TUCSON   520.748.4400

Gary M. Munsinger Has Resigned from RCT’s Board of Directors

6.19.2018

ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition

5.29.2018

U.S. COURT OF APPEALS CONFIRMS THE VALIDITY RCT’S PATENT COVERING VIMPAT® (LACOSAMIDE)

5.23.2018

DisperSol Technologies Raising 27 Million and Initiating Phase II Trials of DST-0509 in Iron Overload Disorder

4.27.2018

Distributed Bio Announces SuperHuman Platform License Agreement With Pfizer Inc.

2.28.2018

UCB’s VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients

11.6.2017

CDC RECOMMENDS SHINGRIX AS THE PREFERRED VACCINE FOR THE PREVENTION OF SHINGLES FOR ADULTS AGED 50 AND OLDER

10.25.2017

SHINGRIX APPROVED IN THE US FOR PREVENTION OF SHINGLES IN ADULTS AGED 50 AND OVER

10.23.2017

CyMedica Orthopedics® announces FDA clearance for e-vive™, the first app-driven muscle activation therapy and patient engagement solution for pre and post-operative knee surgery rehabilitation

1.17.2017

DisperSol Names Dr. Edward M. Rudnic as CEO, RCT Leads $12 Million Funding Round

11.9.2016